Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,574.80
(
-0.62%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
104.67
(
0.23%
)
Bitcoin
70,561.99
(
0.95%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 69994

Friday, 12/12/2008 4:58:33 PM

Friday, December 12, 2008 4:58:33 PM

Post# of 257262
>…looking at the efficacy & safety profiles of the two doses, perhaps NVS should test a lower than 0.5mg dose.<

Too late for that now—the lowest dose in the FREEDOMS and FREEDOMS-2 trials—as well as their open-label extension studies—is 0.5mg.

The 1.25mg dose is probably dead from a commercialization standpoint.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up